Bevacizumab in stage II-III colon cancer: 5-year update of the National Surgical Adjuvant Breast and Bowel Project C-08 trial

Journal of Clinical Oncology

Volumn 31, Issue 3, 2013, Pages 359-364

  Allegra, Carmen J ^a,c   Yothers, Greg ^a,b   O'Connell, Michael J ^a   Sharif, Saima ^a   Petrelli, Nicholas J ^a,d   Lopa, Samia H ^a,b   Wolmark, Norman ^a  

^a ALLEGHENY GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c UNIVERSITY OF FLORIDA   (United States)

^d HELEN F GRAHAM CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN;

ADULT; AGED; ARTERIAL THROMBOEMBOLISM; ARTICLE; BLEEDING; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; COLON ADENOCARCINOMA; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; DRUG DOSE REGIMEN; FEMALE; FOLLOW UP; HAZARD RATIO; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PAIN; PRIORITY JOURNAL; PROTEINURIA; TREATMENT DURATION; VENOUS THROMBOEMBOLISM; WOUND COMPLICATION;

ADENOCARCINOMA; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLONIC NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS;

EID: 84873328631     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.44.4711     Document Type: Article

References (27)

1. André T, Boni C, Mounedji-Boudiaf L, et al: Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350:2343-2351, 2004 (Pubitemid 38702845)
2. Kuebler JP, Wieand HS, O'Connell MJ, et al: Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: Results from NSABP C-07. J Clin Oncol 25:2198-2204, 2007 (Pubitemid 46954643)
3. Giantonio BJ, Catalano PJ, Meropol NJ, et al: Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 25:1539-1544, 2007 (Pubitemid 46733080)
4. Saltz LB, Clarke S, Díaz-Rubio E, et al: Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: A randomized phase III study. J Clin Oncol 26:2013-2019, 2008.
5. [Errata: J Clin Oncol 26:3110, 2008
6. and J Clin Oncol 27:653, 2009]
7. Kozloff M, Yood MU, Berlin J, et al: Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: The BRiTE observational cohort study. Oncologist 14:862-870, 2009
8. Van Cutsem E, Rivera F, Berry S, et al: Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: The BEAT study Ann Oncol 20 1842-1847, 2009
9. Allegra CJ, Yothers G, O'Connell MJ, et al Initial safety report of NSABP C-08: A randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer. J Clin Oncol 27:3385-3390, 2009
10. Allegra CJ, Yothers G, O'Connell MJ, et al Phase III trial assessing the efficacy of bevacizumab in stages II and III carcinoma of the colon: Results of NSABP protocol C-08. J Clin Oncol 29:11-16, 2011
11. White SJ, Freedman LS: Allocation of patients to treatment groups in a controlled clinical study. Br J Cancer 37:849-857, 1978 (Pubitemid 8344907)
12. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
13. Cox DR: Regression models and life tables J Royal Stat Soc Series B 34:187-220, 1972
14. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration Cancer Chemother Rep 50:163-170, 1966
15. 2 from contingency tables, and the calculation of P. J Royal Stat Soc 85:87-94, 1922
16. Lachin JM: Statistical considerations in the intent-to-treat principle. Control Clin Trials 21:167-189, 2000 (Pubitemid 30259147)
17. Klein JP, Moeschberger ML: Survival Analysis: Techniques for Censored and Truncated Data. New York, NY, Springer, 2003
18. De Gramont A, Van Custem E, Tabernero J, et al: AVANT: Results from a randomized, three-arm multinational phase III study to investigate bevacizumab with either XELOX or FOLFOX4 versus FOLFOX4 alone as adjuvant treatment for colon cancer. J Clin Oncol 29:2011 (suppl 4; abstr 362)
19. Ebos JM, Lee CR, Cruz-Munoz W, et al: Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 15:232-239, 2009
20. Paèz-Ribes M, Allen E, Hudock J, et al: Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15:220-231, 2009
21. Loges S, Mazzone M, Hohensinner P, et al: Silencing or fueling metastasis with VEGF inhibitors: Antiangiogenesis revisited. Cancer Cell 15:167-170, 2009
22. Reynolds AR, Hart IR, Watson AR, et al: Stimulation of tumor growth and angiogenesis by low concentrations of RGD-mimetic integrin inhibitors. Nat Med 15:392-400, 2009
23. Ellis LM, Reardon DA: Cancer: The nuances of therapy. Nature 458:290-292, 2009
24. Saltz LB, Niedzwiecki D, Hollis D, et al: Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III coloncancer: Results of CALGB 89803. J Clin Oncol 25:3456-3461, 2007 (Pubitemid 47310883)
25. Ychou M, Raoul JL, Douillard JY, et al: A phase III randomised trial of LV5FU2 + irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802). Ann Oncol 20:674-680, 2009
26. Van Cutsem E, Labianca R, Bodoky G, et al: Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. J Clin Oncol 27:3117-3125, 2009
27. Alberts SR, Sargent DJ, Smyrk TC, et al: Adjuvant mFOLFOX6 with or without cetuxiumab (Cmab) in KRAS wild-type (WT) patients (pts) with resected stage III colon cancer (CC): Results from NCCTG Intergroup Phase III Trial N0147. J Clin Oncol 28:262s, 2010 (suppl; abstr CRA3507)